<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### Database Entries (Feb 16)
Dampalla CS, Zhang J, et int., and Chang K. [‚ÄúPost-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.‚Äù](/search/?article=Dampalla21) _bioRxiv_, 2021. [doi.org/10.1101/2021.02.05.429937](https://doi.org/10.1101/2021.02.05.429937).
### Database Entries (Feb 16)
Lu Q, Zhang Z, et int., and Tong A. [‚ÄúDevelopment of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.‚Äù](/search/?article=Lu21) _Journal of Nanobiotechnology_, 2021. [doi.org/10.1186/s12951-021-00768-w](https://doi.org/10.1186/s12951-021-00768-w). \[[PubMed33514385](https://www.ncbi.nlm.nih.gov/pubmed/33514385/)\] \[[PMC7844813](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844813/)\]
### Database Entries (Feb 16)
Martinez DR, Schaefer A, et int., and Sheahan TP. [‚ÄúEarly therapy with remdesivir and antibody combinations improves COVID-19 disease in mice.‚Äù](/search/?article=Martinez21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.27.428478](https://doi.org/10.1101/2021.01.27.428478). \[[PubMed33532765](https://www.ncbi.nlm.nih.gov/pubmed/33532765/)\] \[[PMC7852229](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852229/)\]
### Database Entries (Feb 16)
Miao X, Luo Y, et int., and Xu Y. [‚ÄúA novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy.‚Äù](/search/?article=Miao20) _mAbs_, 2020. [doi.org/10.1080/19420862.2020.1804241](https://doi.org/10.1080/19420862.2020.1804241). \[[PubMed32804015](https://www.ncbi.nlm.nih.gov/pubmed/32804015/)\] \[[PMC7531490](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531490/)\]
### Database Entries (Feb 16)
Reuschl A, Thorne LG, et int., and Krogan NJ. [‚ÄúHost-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant.‚Äù](/search/?article=Reuschl21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.24.427991](https://doi.org/10.1101/2021.01.24.427991). \[[PubMed33501437](https://www.ncbi.nlm.nih.gov/pubmed/33501437/)\] \[[PMC7836107](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836107/)\]
### Database Entries (Feb 16)
Valenzuela Nieto G, Jara R, et int., and Rojas-Fernandez A. [‚ÄúPotent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.‚Äù](/search/?article=ValenzuelaNieto21) _Scientific Reports_, 2021. [doi.org/10.1038/s41598-021-82833-w](https://doi.org/10.1038/s41598-021-82833-w). \[[PubMed33558635](https://www.ncbi.nlm.nih.gov/pubmed/33558635/)\] \[[PMC7870875](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870875/)\]
### Database Entries (Feb 16)
Zhou Y, Liu Z, et int., and Wang Q. [‚ÄúEnhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD.‚Äù](/search/?article=Zhou21) _Cell Reports_, 2021. [doi.org/10.1016/j.celrep.2021.108699](https://doi.org/10.1016/j.celrep.2021.108699). \[[PubMed33485405](https://www.ncbi.nlm.nih.gov/pubmed/33485405/)\] \[[PMC7802522](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802522/)\]
### [Clinical Trials (Feb 11)](/page/updates/#clinical.trials)
[6 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-02-11)
### Database Entries (Feb 10)
Huang Y, Nguyen AW, et int., and Maynard JA. [‚ÄúIdentification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses.‚Äù](/search/?article=Huang21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.31.428824](https://doi.org/10.1101/2021.01.31.428824).
### Database Entries (Feb 10)
Koenig P, Das H, et int., and Schmidt FI. [‚ÄúStructure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.‚Äù](/search/?article=Koenig21) _Science_, 2021. [doi.org/10.1126/science.abe6230](https://doi.org/10.1126/science.abe6230). \[[PubMed33436526](https://www.ncbi.nlm.nih.gov/pubmed/33436526/)\]
### Database Entries (Feb 10)
Wang C, van Haperen R, et int., and Bosch B. [‚ÄúIsolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein.‚Äù](/search/?article=Wang21c) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.20.346916](https://doi.org/10.1101/2020.10.20.346916).
### Database Entries (Feb 09)
Joaqu√≠n C√°ceres C, Cardenas-Garcia S, et int., and Perez DR. [‚ÄúEfficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model.‚Äù](/search/?article=Caceres21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.27.428428](https://doi.org/10.1101/2021.01.27.428428). \[[PubMed33532776](https://www.ncbi.nlm.nih.gov/pubmed/33532776/)\] \[[PMC7852269](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852269/)\]
### Database Entries (Feb 09)
Li W, Sch√§fer A, et int., and Dimitrov DS. [‚ÄúHigh Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models.‚Äù](/search/?article=Li20j) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.09.007](https://doi.org/10.1016/j.cell.2020.09.007). \[[PubMed32941803](https://www.ncbi.nlm.nih.gov/pubmed/32941803/)\] \[[PMC7473018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473018/)\]
### Database Entries (Feb 09)
Rappazzo CG, Tse LV, et int., and Walker LM. [‚ÄúBroad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.‚Äù](/search/?article=Rappazzo21) _Science_, 2021. [doi.org/10.1126/science.abf4830](https://doi.org/10.1126/science.abf4830). \[[PubMed33495307](https://www.ncbi.nlm.nih.gov/pubmed/33495307/)\]
### Database Entries (Feb 06)
Joyner MJ, Carter RE, et int., and Casadevall A. [‚ÄúConvalescent Plasma Antibody Levels and the Risk of Death from Covid-19.‚Äù](/search/?article=Joyner21) _New England Journal of Medicine_, 2021. [doi.org/10.1056/nejmoa2031893](https://doi.org/10.1056/nejmoa2031893). \[[PubMed33523609](https://www.ncbi.nlm.nih.gov/pubmed/33523609/)\] \[[PMC7821984](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821984/)\]
### [Clinical Trials (Feb 04)](/page/updates/#clinical.trials)
[6 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-02-04)
### Database Entries (Jan 31)
White KM, Rosales R, et int., and Garc√≠a-Sastre A. [‚ÄúPlitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.‚Äù](/search/?article=White21) _Science (New York, N.Y.)_, None. [doi.org/10.1126/science.abf4058](https://doi.org/10.1126/science.abf4058). \[[PubMed33495306](https://www.ncbi.nlm.nih.gov/pubmed/33495306/)\]
### [Clinical Trials (Jan 28)](/page/updates/#clinical.trials)
[7 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-28)
### Database Entries (Jan 25)
Gottlieb RL, Nirula A, et int., and Skovronsky DM. [‚ÄúEffect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19.‚Äù](/search/?article=Gottlieb21) _JAMA_, 2021. [doi.org/10.1001/jama.2021.0202](https://doi.org/10.1001/jama.2021.0202). \[[PubMed33475701](https://www.ncbi.nlm.nih.gov/pubmed/33475701/)\]
### [Clinical Trials (Jan 21)](/page/updates/#clinical.trials)
[6 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-21)
### Database Entries (Jan 19)
Davies SP, Mycroft-West CJ, et int., and Richardson A. [‚ÄúThe hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models.‚Äù](/search/?article=Davies21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.10.426114](https://doi.org/10.1101/2021.01.10.426114).
### Database Entries (Jan 19)
Kim C, Ryu D, et int., and Lee S. [‚ÄúA therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.‚Äù](/search/?article=Kim21) _Nature Communications_, 2021. [doi.org/10.1038/s41467-020-20602-5](https://doi.org/10.1038/s41467-020-20602-5). \[[PubMed33436577](https://www.ncbi.nlm.nih.gov/pubmed/33436577/)\]
### Database Entries (Jan 19)
McCallum M, Marco AD, et int., and Veesler D. [‚ÄúN-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.‚Äù](/search/?article=McCallum21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.14.426475](https://doi.org/10.1101/2021.01.14.426475).
### Database Entries (Jan 19)
Tada T, Fan C, et int., and Landau NR. [‚ÄúAn ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.‚Äù](/search/?article=Tada20) _Cell Reports_, 2020. [doi.org/10.1016/j.celrep.2020.108528](https://doi.org/10.1016/j.celrep.2020.108528). \[[PubMed33326798](https://www.ncbi.nlm.nih.gov/pubmed/33326798/)\] \[[PMC7705358](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705358/)\]
### Database Entries (Jan 15)
Biering SB, Van Dis E, et int., and Stanley SA. [‚ÄúScreening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2.‚Äù](/search/?article=Biering20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.30.424862](https://doi.org/10.1101/2020.12.30.424862).
### [Clinical Trials (Jan 14)](/page/updates/#clinical.trials)
[13 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-14)
### Database Entries (Jan 12)
Kirti R, Roy R, et int., and Sarfaraz A. [‚ÄúIvermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial.‚Äù](/search/?article=Kirti21) _medRxiv_, 2021. [doi.org/10.1101/2021.01.05.21249310](https://doi.org/10.1101/2021.01.05.21249310).
